Emerald Acquisition’s Theravance Biopharma TBPH Stock Holding History

Emerald Acquisition’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.53M	Sell	42,317 -3,807	-8%	-$106K	﹤0.01%	1895
2016 Q2	$1.05M	Buy	+46,124	New	+$996K	﹤0.01%	2150

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's TBPH Position: Q3 2016 in Review

Emerald Acquisition reduced its Theravance Biopharma (TBPH) stake by 8.3% in Q3 2016, selling an estimated $106K and leaving 42,317 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1895.

Emerald Acquisition first reported a position in TBPH in Q2 2016 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

Emerald Acquisition held 42,317 shares of Theravance Biopharma worth $1.53M as of Q3 2016.
Emerald Acquisition sold 3,807 Theravance Biopharma shares in Q3 2016, an estimated $106K.
Theravance Biopharma made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1895 holding.
Emerald Acquisition first reported a position in Theravance Biopharma in Q2 2016 and has held it in 2 quarters since.
100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.